Trial Profile
Phase 1, randomized, double-blind, placebo controlled, single-dose escalation trial to assess safety and Pharmacokinetics of Tildrakizumab
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Apr 2019
Price :
$35
*
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Spondylarthritis
- Focus Adverse reactions; Pharmacokinetics
- 26 Mar 2019 Results of population pharmacokinetic modeling of Tildrakizumab in healthy volunteers and subjects with psoriasis published in the Clinical Pharmacokinetics
- 30 Nov 2018 New trial record